Diabetic drug markets in tumultuous turmoil.

Published: 2007-06-07 06:58:00

Updated: 2007-06-07 06:58:00

A tremendous change seems to explode in the diabetic drug markets by the recent article on the cardiovascular disease risk of Avandia, an diabetic drug for the patients with type II diabetes, published in the New England Journal of Medicine.

Avandia, a derivative of Thiazolidinediones (TZD) a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK